Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers April 30, 2017
Pharmacy Choice - Pharmaceutical News - Amend Surgical Announces 510K Clearance for NanoFUSE BA - April 30, 2017

Pharmacy News Article

 3/15/17 - Amend Surgical Announces 510K Clearance for NanoFUSE BA

By a News Reporter-Staff News Editor at Biotech Week Amend Surgical, Inc., a medical device company focused on enhancing the regenerative capacity of bone replacement products, announced that they have received 510(K) clearance to market NanoFUSE BA as a bone graft extender for spine and orthopedic applications (see also Amend Surgical, Inc.).

NanoFUSE BA is a novel composite containing 45S5 Bioactive Glass and a patent protected carrier that provides optimal surgical handling performance and graft stability. Bioactive glass facilitates operative site graft containment through rapid bone bonding and the subsequent activation of cellular osteogenesis (bone formation). It creates a highly favorable environment for bone fusion as it remodels into the recipient's skeletal system and is an important tool for the orthopedic surgeon. With this most recent clearance Amend Surgical now has two U.S. Food and Drug Administration (FDA) cleared product lines.

"NanoFUSE BA offers our surgeons and their patients a synthetic alternative to NanoFUSE Bioactive Matrix," stated Robby Lane, president and chief executive officer of Amend Surgical. "We are continuing to expand our market presence with the only demineralized bone bioactive glass combination product on the market and are excited about the opportunities offered by the launch of NanoFUSE BA. This product provides surgeons the superior handling characteristics they expect with the long and successful clinical history of bioactive glass." About Amend Surgical Amend Surgical is a specialty medical device company focused on enhancing the bone healing and regenerative capacity of bone grafts, including allograft, xenograft tissues and synthetic materials. The company's pipeline includes novel, clinically evaluated, osteoinductive bone extracts, and will expand in the future to disruptive products based on discovery and development of novel therapeutic additives with tissue-specific regenerative characteristics. View source version on

Keywords for this news article include: Surgery, Bone Research, Medical Devices, Amend Surgical Inc., Surgical Technologies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
May 01: The New Hypertension Guidelines: What are They Telling Us?
Last Chance
May 02: Treatment of Depression and Anxiety in Older Adults
May 03: The Common Cold: An Update for Pharmacy Professionals
May 04: Treatment of Parkinson's Disease and Comorbid Conditions
May 05: Can Pharmacy Malpractice Be a Crime?
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement